NBQ

NBQ (Nantong Bencao Quadriga Medical Technology) is a clinical-stage biopharmaceutical company based in China, specializing in the development of targeted cancer therapies for central nervous system (CNS) malignancies. Established as a joint venture with U.S.-based Quadriga BioSciences, the company utilizes proprietary solute carrier (SLC) transporter technology to target the L-type amino acid transporter 1 (LAT1), which is overexpressed in aggressive tumors and at the blood-brain barrier. Its lead candidate, NBQ72S (also known as QBS10072S), is a first-in-class amino acid analogue designed to selectively enter cancer cells and disrupt DNA replication. The company is currently evaluating NBQ72S in clinical trials for glioblastoma multiforme, brain metastases from breast cancer, and leptomeningeal metastases.